Tests duvakitug in adults with active Crohn's disease
Tests duvakitug against placebo in people with moderately to severely active Crohn's disease.
Key facts
- Who runs it
- Sanofi
- Where
- Cape Town, Claremont, Durban, East London, Kempton Park, and KwaZulu-Natal, South AfricaSee the 6 sitesAlso in 35 other countries, 455 sites
- Trial code
- NCT07184931
- EudraCT 2025-521036-11
- U1111-1314-5319
- Registry title
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 980 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 14 May 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Duvakitug
- Placebo
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderately to severely active Crohn's disease who did not respond well to, lost response to, or could not tolerate earlier treatments.
- Age
- 18 to 80 years. Where local rules allow, 16 to under 18 years if they have reached Tanner Stage 5 of development.
- Sex
- All sexes can join.
- Disease stage
- Moderately to severely active Crohn's disease, confirmed for at least 3 months before the start of the study.
- Earlier treatment
- Must have had an inadequate response, lost response, or intolerance to conventional therapies or advanced therapies. Must not have had earlier anti-TL1A investigational therapy.
Main reasons for not taking part
- Ulcerative colitis or indeterminate colitis
- Two entire missing segments of the terminal ileum, right colon, transverse colon, sigmoid and left colon, or rectum
- Past or current high-grade gastrointestinal dysplasia
- Not on stable doses of conventional therapy before the start, if on such treatment
- Taking prohibited medications or therapies
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to <18 years of age who meet the definition of Tanner Stage 5 for development
- Confirmed diagnosis of moderately to severely active Crohn's Disease (CD) for at least 3 months prior to baseline
- Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies (ATs)
Who cannot take part
- Prior or current high-grade gastrointestinal (GI) dysplasia
- Participants on treatment with but not on stable doses of conventional therapy prior to baseline
- Participants receiving prohibited medications or therapies
- Participants with previous exposure to anti-TL1A investigational therapy; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
- Participants with Ulcerative Colitis (UC) or indeterminate colitis
- Participants with two entire missing segments of the: terminal ileum, right colon transverse colon, sigmoid and left colon, and rectum
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 16 and 80 years old?
This trial is currently available in South Africa.
Also in 35 other countries, 455 sites
- Cape TownHospital not named in the registryTaking people
- ClaremontHospital not named in the registryTaking people
- DurbanHospital not named in the registryTaking people
- East LondonHospital not named in the registryTaking people
- Kempton ParkHospital not named in the registryTaking people
- KwaZulu-NatalHospital not named in the registryTaking people
About the trial
What the trial wants to find out
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include:
Read full original descriptionShow less
The study duration may be up to 35 weeks with:
* Up to 5-week Screening Period. * 12-week Sub-Study 1 (Single Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction). * 12-week Sub-Study 3 (Extended Induction for non-responders). * 6 weeks (45 days) follow-up period for participants who do not enroll into the Pivotal Maintenance Study (EFC18327). The treatment duration will be up to 12 weeks in each sub-study.
The number of scheduled study visits for participants who continue to the Pivotal Maintenance Study (EFC18327) will be up to 8 (Sub-Study 1 and Sub-Study 2) and up to 15 for participants who enroll in Sub-Study 3.
The 3 groups in the trial
- Duvakitug Dose 1Treatment being tested
Subcutaneous (SC) Injection as per protocol
Treatment: Duvakitug
- Duvakitug Dose 2Treatment being tested
SC injection as per protocol
Treatment: Duvakitug
- PlaceboPlacebo, for comparison
SC injection as per protocol
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Plain-language title
- Tests duvakitug in adults with active Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07184931, who can take part
- Record updated
- 21 October 2026